AR and cancer: In these cases, cancer cells adapt to low androgen concentration through clonal selection of cells exhibiting AR amplifications or mutations, intracrine synthesis of testosterone from dehydroepiandrosterone (DHEA), ligand independent activation of AR, or bypassing of normal pathways to facilitate cancer progression (14–16).